Evaxion Biotech A/S (EVAX)

Evaxion Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0.07	0	0	0	0
Gross Profit	0.07	0	0	0	0
Selling, General & Admin	10.35	8.21	6.25	5.67	2.65
Research & Development	11.92	17.06	19.58	10.9	8.22
Operating Expenses	22.27	25.26	25.83	16.57	10.86
Operating Income	-22.2	-25.26	-25.83	-16.57	-10.86
Interest Expense / Income	1.68	1.51	0.92	0.22	1.22
Other Expense / Income	-0.96	-2.83	-2.04	-0.22	-0.07
Pretax Income	-22.92	-23.94	-24.71	-16.58	-12.02
Income Tax	-0.79	-0.77	-0.18	-1.56	-0.83
Net Income	-22.13	-23.17	-24.53	-15.02	-11.2
Shares Outstanding (Basic)	28	23	19	19	19
Shares Change	19.12%	20.86%	1.32%	-	-
EPS (Basic)	-8.10	-9.80	-12.60	-9.70	-8.10
EPS (Diluted)	-8.10	-9.80	-12.60	-9.70	-8.10
Free Cash Flow	-17.78	-26.07	-23.29	-12.62	-7.08
Free Cash Flow Per Share	-6.43	-11.23	-12.13	-6.66	-3.74
Gross Margin	100.00%	-	-	-	-
Operating Margin	-30406.85%	-	-	-	-
Profit Margin	-30308.22%	-	-	-	-
Free Cash Flow Margin	-24353.42%	-	-	-	-
EBITDA	-21.23	-22.43	-23.8	-16.35	-10.8
EBITDA Margin	-29087.67%	-	-	-	-
EBIT	-21.23	-22.43	-23.8	-16.35	-10.8
EBIT Margin	-29087.67%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).